Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists

Christiné S. Rigsby,1 Ashley E. Burch,1 Safia Ogbi,1 David M. Pollock,2 and Anne M. Dorrance1

1Department of Physiology, and 2Vascular Biology Center, Medical College of Georgia, Augusta, Georgia

Submitted 28 February 2007; accepted in final form 25 July 2007

Rigsby CS, Burch AE, Ogbi S, Pollock DM, Dorrance AM. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. Am J Physiol Regul Integr Comp Physiol 293: R1754–R1763, 2007. First published August 1, 2007; doi:10.1152/ajpregu.00145.2007.—Data from the Framingham Heart Study suggest that women may be more sensitive to the deleterious cardiovascular remodeling effects of aldosterone. Previous studies from our laboratory have shown that chronic treatment with spironolactone, a mineralocorticoid receptor (MR) antagonist, decreases ischemic cerebral infarct size and prevents remodeling of the middle cerebral artery (MCA) in male spontaneously hypertensive stroke-prone rats (SHRSP). Therefore, we hypothesized that MR antagonism would reduce ischemic infarct size and prevent MCA remodeling in female SHRSP. Six-week-old female SHRSP were treated for 6 wk with spironolactone (25 or 50 mg·kg−1·day−1) or eplerenone (100 mg·kg−1·day−1) and compared with untreated controls. At 12 wk, cerebral ischemia was induced for 18 h using the intraluminal suture occlusion technique, or the MCA was isolated for controls. At 12 wk, cerebral ischemia was induced for 18 h using the intraluminal suture occlusion technique, or the MCA was isolated for controls.

Address for reprint requests and other correspondence: C. S. Rigsby, Dept. of Physiology, Medical College of Georgia, 1120 15th St. (CA2091), Augusta, Georgia 30912–3000 (e-mail: crigsby@mail.mcg.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
remodeling in female SHRSP. The experiments presented here will assess whether the cerebral vasculature of female SHRSP is as responsive to MR antagonism as has been previously shown in male SHRSP.

MATERIALS AND METHODS

Animals and Treatments

All experiments were conducted in 12-wk-old rats. Virgin female and male SHRSP were obtained from the laboratory’s breeding colony at the Medical College of Georgia. Age-matched virgin female inbred WKY rats were purchased from Harlan (Indianapolis, IN) to serve as normotensive controls for SHRSP and to indicate the severity of the damage from ischemic stroke and the extent of cerebral vessel remodeling. Animals were maintained in a temperature-controlled environment on a 12:12-h light-dark cycle and were provided regular rat chow, with normal sodium content (0.25%; Harlan Teklad, diet no. 8656), and tap water ad libitum. The phytoestrogen content of the diet was not controlled, but all rat groups received the same chow. Six-week-old female SHRSP were treated with spironolactone (25 or 50 mg·kg⁻¹·day⁻¹) or eplerenone (100 mg·kg⁻¹·day⁻¹) in the food for 6 wk. An additional group of 6-wk-old female SHRSP were bilaterally ovariectomized (OVX) and treated with spironolactone (25 mg·kg⁻¹·day⁻¹) in the food for 6 wk; untreated OVX SHRSP were used as controls. Briefly, bilateral ovariectomy was performed under ketamine/xylazine (67/6.6 mg/kg im) anesthesia. Each ovary was exposed via a flank incision and excised using an electocautery. All experiments were approved by the Medical College of Georgia Institutional Animal Care and Use Committee, following the guidelines of the American Physiological Society.

Blood Pressure Measurement

Blood pressure was continuously monitored using telemetry in separate groups of control and spironolactone-treated (25 and 50 mg/kg) SHRSP and control WKY rats for 6 wk, starting at 6 wk of age. Telemetry transmitters (Data Sciences, St. Paul, MN) were implanted in the abdominal aorta, as previously described (16), before spironolactone treatment; averages of 12-h day and night periods for the last week of treatment were reported. In the eplerenone-treated and OVX SHRSP groups, mean arterial pressure was measured during the last week of treatment using tail-cuff plethysmography with a CODA 6 VPR sensor rat-tail blood pressure system (Kent Scientific, Torrington, CT), as described previously (42). Previous studies indicate a very high level of similarity between the measurements obtained using the Kent Scientific tail-cuff system and telemetry (42). Studies comparing the two methods in rodents found that both methods give similar results (22, 25, 57). A study performed in rats comparing the Kent Scientific VPR tail-cuff system and telemetry found 99% correlation in systolic measurements between the two methods (personal communication with Irina Heald, Kent Scientific). For statistical analysis, all intact SHRSP groups, excluding the eplerenone-treated SHRSP, were compared, and the OVX SHRSP groups were compared.

Cerebral Ischemia

In separate groups of rats, cerebral ischemia was induced using a modified version of the intraluminal suture MCAO technique, as previously described (19, 26). Rats were anesthetized using an inhaled isoflurane (2–5%)/oxygen gas mixture. A laser Doppler probe (Perimed, N. Royalton, OH) attached to the skull was used to indicate successful occlusion of the MCA. A piece of 3.0-suture (Dermalon, monofilament nylon), with a rounded tip, was advanced through the internal carotid artery to the branch point of the MCA at the circle of Willis and was secured in place. Eighteen hours post-MCAO, brains were removed, sectioned (2 mm), stained in 2%, 2,3,5-triphenyltetrazolium, and postfixed in 2% paraformaldehyde for 24 h. Pink areas were considered viable tissue, and white areas were considered infarcted regions. Slices were digitized and analyzed using ImageJ software, as described previously (19). The percent hemisphere infarcted (%HI) was determined using an equation to account for edema (50).

Artery Preparation

Separately treated rats that had not undergone MCAO were anesthetized with pentobarbital sodium (100 mg/kg ip) for blood and tissue collection. Heparanized blood samples, obtained via cardiac puncture, were centrifuged, and plasma was collected for electrolyte analysis. The first branch-free segment of the MCA most proximal to the circle of Willis was dissected from the brain and placed in cold physiological salt solution (PSS) (in mmol/l: 141.9 NaCl, 4.7 KCl, 1.7 MgSO₄, 0.5 EDTA, 2.8 CaCl₂, 10.0 HEPES, 1.2 KH₂PO₄, and 5.0 glucose; pH 7.4). The vessel was mounted on two glass micropipettes in a small vessel arteriograph (Living Systems Instrumentation, Burlington, VT). The distal pipette was closed off, creating a zero-flow or blind-sac condition; any vessels possessing leaks were discarded. All experiments in this study were performed without flow. Luminal diameter and left/right wall thickness measurements (in micrometers) were obtained using video microscopy. To maintain vessel integrity, the time between animal death and vessel mounting was kept within 45 min.

Myogenic Tone, Vessel Reactivity, and Passive Structure

Vessels were allowed to equilibrate for 1 h at 75 mmHg in heated, oxygenated PSS. Seventy-five micromillimeters of mercury were chosen based on previous experiments performed in the rat MCA (8, 42). This pressure lies within the autoregulatory range of the rat MCA and is close to the pressure normally experienced by the MCA (11). Initially, luminal diameter measurements were taken at 75 and 125 mmHg to represent active tone. Similar measurements were taken at the end of each experiment in calcium-free conditions for passive tone. Myogenic tone was calculated using the following formula: 1 – (active diameter/passive diameter) * 100 (8).

After active tone measurements were performed, cumulative dose responses (10⁻⁵–10⁻³ mol/l), first to acetylcholine and then to bradykinin, were performed with the intraluminal pressure maintained at 75 mmHg. Luminal diameter measurements were made after a 5-min equilibration at each dose.

Passive vessel structure was assessed in calcium-free PSS containing 2.0 mmol/l EGTA over a range of pressures from 0 to 180 mmHg in 20-mmHg increments. After a 3-min equilibration at each pressure, measurements of luminal diameter and wall thickness (left and right) were taken.

Calculations

Equations used to assess vessel structure were as follows and as described previously (42):

\[ \text{Passive vessel structure} = \frac{1}{2} \times (\text{lumen diameter} - \text{wall thickness}) \]

Equations used to assess vessel structure were as follows and as described previously (42):

\[ \text{Circumferential wall stress} = \frac{\text{(intrapluminal pressure} \times \text{lumen diameter})}{(2 \times \text{wall thickness})} \]

Western Blotting

All animals were anesthetized with pentobarbital sodium (100 mg/kg ip), and the brain was removed at 12 wk of age. Cerebral
arteries, including the middle cerebral, anterior cerebral, ophthalmic, posterior communicating, superior cerebellar, and basilar, were dissected and placed in cold lysis buffer (0.25 M Tri•HCl, 10% SDS, 40% glycerol, 0.25% sodium orthovanadate, 0.25% phenylmethanesulfonfyl fluoride, 0.025% aprotinin, and 0.025% leupeptin; pH = 6.8). Samples were processed, and total protein was quantified using a bicinchoninic acid protein kit (Pierce, Rockford, IL). Samples matched for total protein content were resolved and transferred to polyvinylidene difluoride membranes. The membranes were blocked and then incubated with a mouse monoclonal anti-MR primary antibody (1:200; MRN22B7, a generous gift from laboratory of Dr. Gomez-Sanchez, Jackson, MS) (24), followed by a goat anti-mouse fluorescent secondary antibody (1:10,000; Rockland, Gilbertsville, PA). Stripped membranes were reprobed using a mouse monoclonal fluorescent secondary antibody (1:10,000; Rockland, Gilbertsville, PA) to visualize and quantify the bands. The ratio of MR to β-tubulin was calculated for each band; the ratios were averaged for each group and compared.

Statistics

Statistical significance was determined using two-way repeated-measures ANOVA, with the Bonferroni multiple-comparison posttest for all dose and pressure responses. One-way ANOVA was used for physiological measurements, blood pressure, %HI, percent tone, EC50 data, and β-coefficients with the Bonferroni multiple-comparison posttest. A t-test was used to determine statistical significance for the Western blot data. A P value of <0.05 was considered significant. All values presented are means ± SE; n represents the number of animals. Statistical comparisons were not made between intact and OVX SHRSP groups; these were treated as separate studies.

RESULTS

Part I: Effects of MR Antagonism in Intact Female SHRSP

Blood pressure. Mean arterial pressure was not different between SHRSP groups (P > 0.05, Table 1). Control WKY rats had significantly lower mean arterial pressure compared with all SHRSP groups (P < 0.05, Table 1). Eplerenone-treated SHRSP were not included in the statistical analysis of blood pressure.

Table 1. Physiological parameters

<table>
<thead>
<tr>
<th>Physiological Parameter</th>
<th>SHRSP Control</th>
<th>SHRSP Spir 25 mg/kg</th>
<th>SHRSP Spir 50 mg/kg</th>
<th>SHRSP Eplerenone</th>
<th>WKY Control</th>
<th>P &lt; 0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean arterial pressure, mmHg</td>
<td>141 ± 4 (5)</td>
<td>134 ± 4 (5)</td>
<td>137 ± 9 (4)</td>
<td>134 ± 6 (6)</td>
<td>98 ± 1* (5)</td>
<td>WKY vs. all other groups*†</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>172.6 ± 2.7 (8)</td>
<td>194.5 ± 3.4* (8)</td>
<td>180.7 ± 3.0 (5)</td>
<td>177.6 ± 3.1 (5)</td>
<td>182.1 ± 2.3 (7)</td>
<td>Spir 25 vs. all other groups*</td>
</tr>
<tr>
<td>Heart weight, g</td>
<td>0.724 ± 0.02 (8)</td>
<td>0.808 ± 0.02* (8)</td>
<td>0.708 ± 0.01 (5)</td>
<td>0.694 ± 0.02 (5)</td>
<td>0.594 ± 0.01* (7)</td>
<td>WKY and Spir 25 vs. all other groups*</td>
</tr>
<tr>
<td>Heart-to-body weight ratio × 100</td>
<td>0.419 ± 0.01 (8)</td>
<td>0.416 ± 0.01 (8)</td>
<td>0.392 ± 0.005 (5)</td>
<td>0.391 ± 0.01 (5)</td>
<td>0.326 ± 0.005* (7)</td>
<td>WKY vs. all other groups*</td>
</tr>
<tr>
<td>Brain weight, g</td>
<td>1.665 ± 0.01 (5)</td>
<td>1.667 ± 0.02 (8)</td>
<td>1.662 ± 0.03 (5)</td>
<td>1.604 ± 0.02 (5)</td>
<td>1.918 ± 0.01* (7)</td>
<td>WKY vs. all other groups*</td>
</tr>
<tr>
<td>Brain-to-body weight ratio × 100</td>
<td>0.951 ± 0.02 (5)</td>
<td>0.858 ± 0.01* (8)</td>
<td>0.898 ± 0.01 (5)</td>
<td>0.904 ± 0.02 (5)</td>
<td>1.050 ± 0.01* (7)</td>
<td>WKY vs. all other groups*</td>
</tr>
<tr>
<td>Plasma potassium, mmol/l</td>
<td>4.6 ± 0.4 (6)</td>
<td>4.5 ± 0.1 (6)</td>
<td>5.0 ± 0.2 (6)</td>
<td>4.8 ± 0.4 (5)</td>
<td>NS</td>
<td>Spine 25 vs. SHRSP control†</td>
</tr>
<tr>
<td>Plasma sodium, mmol/l</td>
<td>141 ± 2.8 (6)</td>
<td>141.2 ± 1.9 (6)</td>
<td>140.1 ± 1.1 (6)</td>
<td>145.6 ± 0.4 (5)</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± SE; nos, in parentheses are n values. Treatments were started at 6 wk of age in female spontaneously hypertensive stroke-prone rats (SHRSP). All parameter were measured in 12-wk-old female SHRSP and Wistar Kyoto (WKY) rats. Spir, spironolactone; NS, not significant. *P < 0.05 vs. all other groups; †P < 0.05 vs. SHRSP-control. †Eplerenone-treated SHRSP were not included in the statistical comparison for mean arterial pressure.

Physiological parameters. Body and heart weight were increased in spironolactone-treated (25 mg/kg) SHRSP compared with all other groups, but the heart-to-body weight ratio was not different compared with all other groups (Table 1). The brain-to-body weight ratio was increased in spironolactone-treated (25 mg/kg) SHRSP compared with control SHRSP (Table 1). Spironolactone (50 mg/kg) and eplerenone had no effect on body, heart, brain, heart-to-body weight ratio, and brain-to-body weight ratio compared with control SHRSP (P < 0.05, Table 1). Heart weight and heart-to-body weight ratios were lower in control WKY rats compared with all SHRSP groups (P < 0.05, Table 1). Brain weight and brain-to-body weight ratios were significantly larger in control WKY rats compared with all SHRSP groups (P < 0.05, Table 1). Plasma sodium and potassium levels were not significantly different between groups (P > 0.05, Table 1).

Effect of MR antagonists on ischemic cerebral infarct size. Spironolactone (25 and 50 mg/kg) and eplerenone had no effect on ischemic infarct size, as expressed as the %HI compared with control SHRSP (P > 0.05, Fig. 1). %HI was significantly lower in control WKY rats compared with all SHRSP groups, indicating less damage from MCAO (P < 0.05, Fig. 1).

Effect of MR antagonists on MCA mechanics and reactivity. MCA structure. MCAs from female SHRSP underwent inward-eutrophic remodeling, as indicated by the smaller luminal and outer diameters, with no change in wall area compared with control WKY rats (P < 0.05, Fig. 2 and Table 2). Control WKY rats had significantly larger luminal and outer diameters compared with all SHRSP groups (P < 0.05, Fig. 2). Wall thickness and wall-to-lumen ratio were significantly smaller in control WKY rats compared with all SHRSP groups (P < 0.05, Table 2). Wall area was not different between groups (P > 0.05, Table 2). Eplerenone treatment increased luminal diameter and decreased wall thickness and wall-to-lumen ratio compared with control and spironolactone-treated (25 mg/kg) SHRSP (P < 0.05), but did not affect outer diameter (P > 0.05) (Fig. 2 and Table 2). Wall-to-lumen ratio was significantly decreased in spironolactone (50 mg/kg) compared with
Effects of Spironolactone in OVX SHRSP

Due to the lack of a difference of MR antagonists on cerebral infarct size or MCA structure in intact SHRSP, similar studies were carried out using spironolactone (25 mg/kg) treatment in OVX SHRSP to elucidate if the absence of an effect of spironolactone was due to the presence of estrogen.

Physiological parameters. Spironolactone (25 mg/kg) had no effect on mean arterial blood pressure, body weight, heart weight, heart-to-body weight ratio, or brain weight in OVX SHRSP (*P < 0.05, Table 3). Mean arterial pressure was not different between intact and OVX SHRSP (*P < 0.05, ANOVA). However, the brain-to-body weight ratio was lower in spironolactone-treated (25 mg/kg) OVX SHRSP (*P < 0.05, Table 3). There was no difference in plasma sodium levels between groups (*P > 0.05, Table 3), but spironolactone (25 mg/kg) treatment significantly increased plasma potassium levels in OVX SHRSP (*P < 0.05, Table 3).

Effect of spironolactone on ischemic cerebral infarct size in OVX SHRSP. Spironolactone (25 mg/kg) treatment had no effect on ischemic infarct size, as indicated by the lack of a difference in %HI between groups (*P > 0.05, Fig. 4). %HI is similar between control and OVX SHRSP.

Effect of spironolactone on MCA mechanics and reactivity in OVX SHRSP. MCA structure. Spironolactone (25 mg/kg) treatment decreased lumen and outer diameters in OVX

The paradoxical leftward shift in control WKY rats compared with all SHRSP groups (*P < 0.05, ANOVA).
Table 2. Vessel dynamics

<table>
<thead>
<tr>
<th>Vessel Dynamics</th>
<th>SHRSP Control (9)</th>
<th>SHRSP Spir 25 mg/kg (5)</th>
<th>SHRSP Spir 50 mg/kg (5)</th>
<th>SHRSP Eplerenone (5)</th>
<th>WKY Control (6)</th>
<th>P &lt; 0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wall thickness at 80 mmHg, μm</td>
<td>38.0±1.4</td>
<td>37.6±1.7</td>
<td>33.6±1.1</td>
<td>31.6±1.4†</td>
<td>26.0±0.7*</td>
<td>WKY vs. all groups*</td>
</tr>
<tr>
<td>Wall-to-lumen ratio at 80 mmHg</td>
<td>0.16±0.01</td>
<td>0.16±0.01</td>
<td>0.13±0.01†</td>
<td>0.12±0.01†</td>
<td>0.08±0.002*</td>
<td>Epl vs. SHRSP control and Spir 25†</td>
</tr>
<tr>
<td>Wall area at 80 mmHg, μm²</td>
<td>15,045.6±528.2</td>
<td>15,203.4±780.6</td>
<td>14,359.6±491.2</td>
<td>13,842.2±620.6</td>
<td>13,423.5±478.4</td>
<td>NS</td>
</tr>
<tr>
<td>Remodeling index at 80 mmHg, %</td>
<td>94.6</td>
<td>93.7</td>
<td>96.1</td>
<td>98.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth index at 80 mmHg, %</td>
<td>12.1</td>
<td>13.3</td>
<td>7.0</td>
<td>3.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bradykin log EC₅₀</td>
<td>−8.99±0.4</td>
<td>−8.32±0.1</td>
<td>−8.20±0.2</td>
<td>−4.47±3.1</td>
<td>−9.63±1.3</td>
<td>NS</td>
</tr>
<tr>
<td>Myogenic tone at 75 mmHg, %</td>
<td>13.0±2.7</td>
<td>15.1±2.3</td>
<td>11.1±3.6</td>
<td>21.2±5.4</td>
<td>10.2±2.4</td>
<td>NS</td>
</tr>
<tr>
<td>β-Coefficient</td>
<td>4.76±0.4§</td>
<td>3.96±0.6§</td>
<td>5.25±0.2§</td>
<td>7.23±1.0†</td>
<td>8.84±0.2</td>
<td>Epl vs. SHRSP control and Spir 25† vs. WKY§</td>
</tr>
</tbody>
</table>

Values are mean ± SE; nos. in parentheses are n values. Treatments were started at 6 wk of age in female SHRSP. All experiments were conducted in 12-wk-old female SHRSP and WKY rats. Only the measurements made at 80 mmHg for the structural parameters are displayed in the table, but are representative of the data taken over the range of pressures (0 to 180 mmHg). Epl, eplerenone. The P values indicated stand for the ANOVAs from the entire curve. *P < 0.05 vs. all other groups. †P < 0.05 vs. SHRSP-control and SHRSP-Spir 25 mg/kg. ‡P < 0.05 vs. SHRSP-Spir 25 mg/kg. §P < 0.05 vs. WKY control.

SHRSP (P < 0.05, Fig. 5). Lumen and outer diameters for control SHRSP and WKY rats were included as a reference to indicate the severity of eutrophic remodeling in OVX SHRSP. Wall thickness and wall-to-lumen ratio were also decreased in spironolactone-treated (25 mg/kg) OVX SHRSP (P < 0.05, Table 4). Wall area was not altered by spironolactone (25 mg/kg) treatment in OVX SHRSP (P < 0.05, Table 4). Only the measurements made at 80 mmHg are displayed in Table 4, but are representative of the data taken over the range of pressures. The P values indicated in Table 4 are of the ANOVAs from the entire curve for each structural parameter.

MCA COMPLIANCE AND STIFFNESS. Spironolactone (25 mg/kg) treatment had no effect on compliance in OVX SHRSP, as there was not a shift in the stress-strain curve (Fig. 6). Vessel stiffness was also not altered by spironolactone (25 mg/kg) treatment in OVX SHRSP, as indicated by the lack of a change in the β-coefficient (P > 0.05, Table 4).

MCA REACTIVITY TO ACETYLCHELONE AND BRADYKININ. Spironolactone (25 mg/kg) treatment had no effect on the percent increase in luminal diameter in response to acetylcholine or bradykinin over the range of doses in OVX SHRSP (data not shown). The log EC₅₀ values were also unchanged, suggesting there was no difference in sensitivity to acetylcholine (data not shown) or bradykinin (P > 0.05, Table 4) in the MCA of OVX SHRSP.

MCA MYOGENIC TONE. Spironolactone (25 mg/kg) treatment significantly increased myogenic tone at 75 mmHg in the OVX SHRSP compared with nontreated OVX SHRSP (P < 0.05, Table 4). Myogenic tone was also increased at 125 mmHg in the spironolactone-treated (25 mg/kg) compared with non-treated OVX SHRSP (P < 0.05, 28.9 ± 6.8 vs. 11.0 ± 3.4%).

Sexual Dimorphism of MR Expression in Cerebral Arteries from SHRSP

For the first study (Fig. 7A), 12-wk-old male and female SHRSP (n = 5 per sex) were used. Protein expression of the MR assessed by Western blotting was significantly increased in cerebral arteries from female SHRSP compared with male SHRSP, expressed as a ratio of MR to β-tubulin (P < 0.05, Fig. 7A). For the second study (Fig. 7B), 6-wk-old female SHRSP (n = 10) were OVX, as described in the MATERIALS AND METHODS section. Twelve-week-old OVX and intact, female SHRSP (n = 9) were used. Protein expression of the MR
assessed by Western blotting was not different in cerebral arteries from intact compared with OVX SHRSP, expressed as a ratio of MR to β-tubulin (P > 0.05, Fig. 7B).

DISCUSSION

Previously, we have shown a 50% decrease in cerebral infarct size and prevention of inward eutrophic remodeling of the cerebral vasculature in male SHRSP treated with spironolactone (18, 42), while, in the present study, we did not observe a similar effect of spironolactone in female SHRSP. One difference between these studies and the present study was the route of administration of the spironolactone. However, we have shown that the same dose and route of administration of spironolactone, as used in the present study, caused a reversal of vessel remodeling in older male SHRSP (41). Although eplerenone treatment in female SHRSP elicited some effects on MCA structure, the magnitude of these changes was not as great as the changes observed in male SHRSP treated with eplerenone (100 mg·kg⁻¹·day⁻¹, in food), where the MCA luminal diameter of the treated rats was larger than that of a WKY rat, independent of blood pressure (40). Remarkably, there was also no effect of MR antagonism on cerebral infarct size in intact or OVX SHRSP. The lack of a robust effect of MR antagonism in female SHRSP is even more perplexing, considering they have increased cerebral artery MR expression compared with male SHRSP.

In humans, MR antagonism lowers blood pressure (7, 33). However, mean arterial pressure, measured using telemetry or...
A shift in the MCA stress-strain curve from OVX SHRSP. Circumferential wall stress and strain were calculated from the table, but are representative of the data taken over the range of pressures (0–180 mmHg). The P values indicated stand for the ANOVAs from the entire curve.

tail-cuff plethysmography, was not different between control and spironolactone-treated SHRSP groups. This is in agreement with studies showing that MR antagonism has no effect on blood pressure in male SHRSP (18, 41–43, 45) and suggests that MR activation is also not involved in blood pressure maintenance in female SHRSP (32). Previous studies suggest that OVX does not affect blood pressure in spontaneously hypertensive rats and Sprague-Dawley rats (39, 54), but OVX does increase blood pressure in SHRSP (48). It should be noted that the SHRSP were salt-loaded and fed a Stroke-Prone Rodent diet, whereas our studies were performed in nonsalt-loaded rats fed normal chow.

The prevalence of cardiovascular disease is increased in men compared with women before age 55 yr, but by age 65 yr, this is reversed, presenting the possibility that estrogen loss at menopause may be a contributing factor (53). Sex differences in the regulation of blood pressure and the renin-angiotensin-aldosterone system found in humans have also been shown in animal models (27, 37). Studies in female rats indicate that levels of angiotensin-converting enzyme, expression of angiotensin type 1 receptor, and aldosterone secretion are decreased in the presence of estrogen (31, 46, 52). In aged SHRSP, plasma aldosterone is lower in females than in males (28), which could explain the increased cerebral artery MR expression in female SHRSP in the present study.

MR antagonism was effective in reducing mortality in heart failure patients enrolled in two clinical trials, RALES and EPHESUS (34, 35). In these trials, the percentage of female patients included was between 27 and 30%, but the results were not specifically evaluated for sex differences. Animal studies evaluating sex differences of MR antagonism or the effects of MR antagonism in females are limited. One study involving intracerebroventricular administration of a MR antagonist, RU28318, into Wistar rats found that females were less sensitive to central MR antagonism than males (36). Here, neither MR antagonist used could elicit similar dramatic effects in intact or OVX SHRSP, as were seen in male SHRSP in our laboratory’s previous studies (18, 40–42). The lack of an effect of MR antagonism in female SHRSP, even in the presence of increased MR expression, could indicate a sex difference in the metabolism of the antagonists. Pharmacokinetic studies using eplerenone indicate that male rats metabolize the drug more than female rats, due to increased expression of cytochrome P-450 enzymes (10). Since the activity of spironolactone is due to its metabolites, mainly canrenone (17), MR antagonism may be more effective in males because of increased metabolism, as is the case in the present study. It is feasible that both doses of spironolactone used may not have been sufficient to block the MR in female SHRSP; however, a higher dose would have interfered with the estrous cycle (17), causing extraneous effects.

The classical caveat of using spironolactone is its lack of specificity. While it is an excellent MR antagonist, it also possesses anti-androgenic and weak progestin effects (47). However, the present studies also included eplerenone, a more specific, but less efficacious MR antagonist (47). We have recently shown that eplerenone treatment in male SHRSP elicits similar effects as we have shown with spironolactone treatment (42), i.e., prevention of MCA remodeling (40). This suggests that the possible anti-androgenic effects are not playing a role in the effects we observe with spironolactone in male or female SHRSP. Eplerenone treatment of the female SHRSP did offer some improvements in MCA structure, but the magnitude of these changes is very small compared with the changes observed in male SHRSP treated with MR antagonists (40, 42). Even though there were small improvements in MCA structure, stiffness of MCAs from eplerenone-treated SHRSP was increased compared with control SHRSP, which may partially explain why infarct size was unchanged. MCA compliance was not changed by spironolactone treatment at 50

### Table 4. Vessel dynamics for OVX SHRSP

<table>
<thead>
<tr>
<th>Vessel Dynamics</th>
<th>Experimental Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SHRSP OVX</td>
</tr>
<tr>
<td>Wall thickness at 80 mmHg, μm</td>
<td>42.0±3.5 (7)</td>
</tr>
<tr>
<td>Wall-to-lumen ratio at 80 mmHg</td>
<td>0.21±0.03 (7)</td>
</tr>
<tr>
<td>Wall area at 80 mmHg, μm²</td>
<td>15,186.9±690.7 (7)</td>
</tr>
<tr>
<td>Bradykinin log EC₅₀</td>
<td>−8.66±0.3 (7)</td>
</tr>
<tr>
<td>Myogenic tone at 75 mmHg, %</td>
<td>7.28±2.6 (7)</td>
</tr>
<tr>
<td>β-Coefficient</td>
<td>5.54±0.6 (7)</td>
</tr>
</tbody>
</table>

Values are mean ± SE; nos. in parentheses are n values. Bilateral ovariectomy was performed and spironolactone treatment was started at 6 wk of age in female SHRSP. All experiments were conducted in 12-wk-old OVX SHRSP. Only the measurements made at 80 mmHg for the structural parameters are displayed in the table, but are representative of the data taken over the range of pressures (0–180 mmHg).
mg/kg, which may be due to the increased probability of spironolactone to elicit nonspecific effects at higher doses. Also, myogenic tone in spironolactone-treated OVX SHRSP was increased, which is similar to our findings in male SHRSP, where there was an enhancement of overall contractile ability of the MCA (42). Despite this, none of the changes observed in MCA structure were sufficient to reduce the damage caused by cerebral ischemia.

The weak progestin activity of spironolactone can cause disruption of ovulation, but this occurs in rats at a dose that is twofold higher than the highest dose utilized in the present study (17). OVX SHRSP were treated with spironolactone to evaluate whether estrogen may have been modulating the actions of the MR; however, there were only small changes in MCA structure. Interestingly, plasma potassium was increased in these rats. Dietary potassium supplementation and a subsequent increase in plasma potassium has been shown to improve MCA structure (19, 56), presenting the possibility that the small improvements in vascular structure in the spironolactone-treated SHRSP are a result of potassium.

Another limitation of the present study is that the estrous cycle was not monitored. Previous studies show that the cycling status of the female rat affects the damage caused by cerebral ischemia in SHRSP (6). Female SHRSP in the proestrus phase (high circulating estrogen) have ~24% smaller infarcts compared with SHRSP in the metestrus phase (low circulating estrogen) of the cycle. However, it is important to note that SHRSP used in the study were first crossed with WKY rats to alter the sensitivity to experimental stroke (4), and the method of ischemic stroke induction is different. Carswell et al. used a transcranial ischemia technique (5), whereas our study adapted the intraluminal suture occlusion technique (26), although both methods were permanent. Therefore, differences in the techniques employed and the strain of rats used between the two studies could explain the differences between our results. However, in our studies, the variability in infarct size was low within each group of intact SHRSP (SE of the mean of less than ±2.0% HI per group), suggesting either that the female SHRSP were in the same point of the cycle at induction of ischemia, or that the severe damage caused by ischemic stroke in this model cannot be altered by high circulating estrogen levels in the proestrus cycling phase. We would have expected much greater variability in our results, if damage incurred by cerebral ischemia depended on the cycling phase. To highlight this point, OVX SHRSP did not have increased ischemic stroke damage compared with intact control SHRSP. Many studies using normotensive rats have shown that OVX increases damage caused by ischemic stroke (1, 29).

A study performed by Alkayed et al. (1) utilized intact and OVX SHRSP and showed that OVX increased infarct size after MCAO, but in that study the investigators used an ischemia (2 h)-reperfusion (22 h) technique, which has an entirely different pathology from the permanent MCAO technique and may explain differences between our findings. However, in a study performed by Carswell et al. (5), exogenous administration of estrogen did not confer protection after transcranial MCAO in OVX SHRSP.

In summary, the present study brings to light an apparent sexual dimorphism in the actions of MR antagonists in SHRSP. The disparity may be partially due to the difference in MR expression in the cerebral arteries. Our data add to the increasing body of literature acknowledging sex differences of the renin-angiotensin-aldosterone system and their involvement in the development and progression of cardiovascular disease and hypertension. Further study is warranted to elucidate the effects that genetics or disease pathology play in creating these sex differences. Data from these studies could lead to more sex-specific therapies for treating patients with cardiovascular disease.

ACKNOWLEDGMENTS

We thank Hiram Ocasio for time and surgical expertise in the telemetry studies.

GRANTS

This work was supported by National Heart, Lung, and Blood Institute Grants HL077385 (A. M. Dorrance) and HL64776 (D. M. Pollock).
REFERENCES

5. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
11. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
12. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
17. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
18. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
23. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
24. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
29. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
30. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
32. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, 8. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
35. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
36. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
38. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, 8. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
41. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
42. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
43. Cook CS, Zhang L, Ames GB, Fischer J, Zhang J, Levin S.
44. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, 8. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
47. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
48. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
50. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, 8. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
53. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
54. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.
56. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, 8. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
59. Carswell HV, Anderson NH, Clark JS, Graham D, Jeffs B, Dominic-
60. Coulson RJ, Chesler NC, Vitullo L, Cipolla MJ.